Volume 53, Issue 6, Pages (December 2010)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.

Volume 63, Issue 1, Pages (July 2015)

Volume 46, Issue 3, Pages (March 2007)

The impact of hepatitis E in the liver transplant setting

Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen

Inflammasomes in liver diseases

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

Volume 59, Issue 6, Pages (December 2013)

Volume 62, Issue 4, Pages (April 2015)

Hepatorenal Syndrome.

Ascites and Hepatorenal Syndrome: Pathophysiology and Management

Cláudia Fagundes, MD, Pere Ginès, MD, PhD

Julien Bissonnette, Dominique Valla, Pierre-Emmanuel Rautou

Volume 61, Issue 6, Pages (December 2014)

Volume 51, Issue 6, Pages (December 2009)

The impact of hepatitis E in the liver transplant setting

Reactive oxygen species in the normal and acutely injured liver

Cédric Coulouarn, Bruno Clément Journal of Hepatology

Matthew T. Kitson, Stuart K. Roberts Journal of Hepatology

Immigration and viral hepatitis

Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute- on-chronic liver failure Manuel Romero-Gómez, Sara Montagnese, Rajiv.

Volume 66, Issue 1, Pages 1-4 (January 2017)

Ype P. de Jong, Charles M. Rice, Alexander Ploss Journal of Hepatology

Living donor liver transplantation: is the hype over?

Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management Vicente Arroyo, Jordi Colmenero Journal of.

Mesenchymal stromal cell therapy for liver diseases

Volume 69, Issue 2, Pages (August 2018)

Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure” Rakhi Maiwall,

Jordan J. Feld, Graham R. Foster Journal of Hepatology

Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw Journal of Hepatology

Hepatitis C core protein – The “core” of immune deception?

Volume 61, Issue 1, Pages S108-S119 (November 2014)

Amalia Gastaldelli, Giulio Marchesini Journal of Hepatology

Acute-on chronic liver failure

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study Gyuri Kim, Suk-Yong Jang, Chung.

Vicente Arroyo, Carlos Terra, Pere Ginès Journal of Hepatology

Volume 61, Issue 1, Pages S69-S78 (November 2014)

Volume 69, Issue 2, Pages (August 2018)

Genomic risk of hepatitis C-related hepatocellular carcinoma

Andres Cardenas, Pere Ginès Journal of Hepatology

Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore

Volume 55, Issue 2, Pages (August 2011)

EASL Clinical Practice Guidelines: Wilson’s disease

Roberto de Franchis, Aleksander Krag Journal of Hepatology

Volume 41, Issue 4, Pages (October 2004)

The changing role of beta-blocker therapy in patients with cirrhosis

Volume 57, Issue 5, Pages (November 2012)

Volume 150, Issue 7, Pages (June 2016)

Cédric Coulouarn, Bruno Clément Journal of Hepatology

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Paul C. Adams, James C. Barton Journal of Hepatology

Immigration and viral hepatitis

Global burden of alcoholic liver diseases

HCV targeting of patients with cirrhosis

Volume 63, Issue 1, Pages (July 2015)

Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice Paolo Angeli, Pere Gines

Incarcerated Umbilical Hernia After Transjugular Intrahepatic Portosystemic Shunt Procedure for Refractory Ascites Ravi K. Mallavarapu, Edwin W. Grimsley

Shunt dysfunction: Is it suitable as the primary end point in transjugular intrahepatic portosystemic shunt trials? Jingzhi Cai, Wengang Guo, Chuangye.

Liver transplantation in children

Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi

Vegetative infection of transjugular intrahepatic portosystemic shunts

Volume 60, Issue 6, Pages (June 2014)

Manuel Hernández-Guerra, Anna Hadjihambi, Rajiv Jalan

Pathogenesis of cholestatic hepatitis C

Donor-recipient matching: Myths and realities

Chimeric mouse model of hepatitis B virus infection

A 360-degree overview of paediatric NAFLD: Recent insights

Volume 60, Issue 6, Pages (June 2014)

Volume 60, Issue 6, Pages (June 2014)

Presentation transcript:

Volume 53, Issue 6, Pages 1135-1145 (December 2010) Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives Elsa Solà, Pere Ginès Journal of Hepatology Volume 53, Issue 6, Pages 1135-1145 (December 2010) DOI: 10.1016/j.jhep.2010.08.001 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Schematic representation of the proposed pathogenesis of ascites and edema formation in cirrhosis. Established therapies are given on the left side and potential new therapies on the right. TIPS, transjugular intrahepatic portosystemic shunt. Journal of Hepatology 2010 53, 1135-1145DOI: (10.1016/j.jhep.2010.08.001) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Schematic representation of the proposed pathogenesis of hypervolemic hyponatremia in cirrhosis. Established therapies are given on the left side and potential new therapies on the right. ∗Vaptans are approved for the management of hypervolemic hyponatremia in cirrhosis in United States and Japan, but not in Europe. Journal of Hepatology 2010 53, 1135-1145DOI: (10.1016/j.jhep.2010.08.001) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Schematic representation of the proposed pathogenesis of hepatorenal syndrome in cirrhosis. Established therapies are given on the left side and potential new therapies on the right. ∗The use of TIPS, transjugular intrahepatic portosystemic shunt, has been reported in some studies but the information is very limited. ∗∗Vasoconstrictors include vasopressin analogues such as terlipressin and α-adrenergic agonists, such as norepinephrine or midodrine. ∗∗∗Albumin is given in combination with vasoconstrictors. Albumin alone is seldom effective. Journal of Hepatology 2010 53, 1135-1145DOI: (10.1016/j.jhep.2010.08.001) Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2010 53, 1135-1145DOI: (10. 1016/j. jhep. 2010 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2010 53, 1135-1145DOI: (10. 1016/j. jhep. 2010 Copyright © 2010 European Association for the Study of the Liver Terms and Conditions